BioLife Solutions, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLFS research report →
Range $31 – $31
Price Chart
About the company
BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions.
- CEO
- Roderick de Greef
- IPO
- 1989
- Employees
- 155
- HQ
- Bothell, WA, US
Get TickerSpark's AI analysis on BLFS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.89B
- P/E
- 37.34
- Fwd P/E
- 64.35
- PEG
- -0.01
- P/S
- 18.35
- P/B
- 4.49
- EV/EBITDA
- 194.95
- Div Yield
- 0.00%
- Gross Margin
- 64.48%
- Op Margin
- 7.25%
- Net Margin
- 49.06%
- ROE
- 13.29%
- ROIC
- 1.71%
Latest fiscal year · YoY change
- Revenue
- $96.21M+17.0%
- Gross Profit
- $62.12M+15.7%
- Op Income
- $-1,081,000
- Net Income
- $-12,130,000+39.9%
- EPS
- $-0.25+43.2%
- OCF Growth
- +138.6%
- FCF Growth
- -92.0%
- 52W High
- $39.76
- 52W Low
- $17.86
- 50D MA
- $35.70
- 200D MA
- $26.62
- Beta
- 1.92
- RSI (14)
- 61
- Avg Volume
- 1.13M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BioLife started 2026 with 25% revenue growth and reaffirmed full-year guidance, but near-term gross margin remains pressured by bag yield issues that management expects to ease later in the year or into early 2027.· May 7, 2026
- Q1 revenue was $27.5 million, up 25% year over year, with adjusted EBITDA of $6.2 million or 22% of revenue, up roughly 15%.
- Biopreservation media (BPM) remained the main growth driver and now represents over 85% of revenue; management said commercial-therapy customers are a growing share of the mix.
- Gross margin fell to 64% from 67% on a GAAP basis and 64% from 68% on an adjusted basis, mainly due to bag yield issues and mix toward bags.
- Full-year 2026 guidance was reaffirmed: revenue of $112.5 million to $115 million, 17% to 20% growth, mid-60s gross margin, positive GAAP net income, and expanding adjusted EBITDA margin.
- Management said newer products and cross-selling are progressing, with PanTHERA still on track for a Q4 launch and CryoCase seeing validation activity and early commercial interest.
BioLife reported Q1 2026 revenue of $27.5 million, up 25% year over year. Adjusted EBITDA was $6.2 million, or 22% of revenue, versus $5.4 million and 24% of revenue in Q1 2025. GAAP gross margin was 64% versus 67% a year ago; adjusted gross margin was 64% versus 68% a year ago. GAAP net income was $1.2 million, or $0.02 per share, versus $0.3 million, or $0.01 per share, in the prior year. For 2026, management reaffirmed revenue guidance of $112.5 million to $115 million, implying 17% to 20% growth, expects gross margin in the mid-60s, positive full-year GAAP net income, and adjusted EBITDA margin expansion.
Rod de Greef said the quarter showed operating leverage from a simplified business focused on high-margin recurring revenue. He emphasized strong momentum in CGT, especially from later-stage and commercial therapies, and said BioLife’s share is strongest where programs are closest to approval or commercialization. His tone was confident but measured: he highlighted growth opportunities in cross-selling, new products, and adjacent strategic investments, while repeatedly noting that some of these initiatives take time because of customer validation cycles.
Troy Wichterman focused on the financial bridge from growth to profitability. He noted Q1 gross margin was pressured by lower-margin bags and the previously discussed yield issue, but said the yield impact is transitory and should unwind during 2026, supporting gross margin expansion. Cash and marketable securities were $111.5 million at March 31, 2026, down from $120.2 million at year-end; cash usage reflected $5.6 million for share withholding taxes, $2.5 million of debt principal payments, and $6.9 million of unfavorable working capital, including a $5.1 million AR increase. He also said the remaining $2.5 million SVB debt is short term, with a June 2026 maturity and a $1.2 million balloon payment due then.
Analysts pressed on the bag issue, asking whether the problem was both mix and scrap/yield. Management said bags carry materially lower gross margin than bottles and that customer notifications will go out shortly, followed by a 90-day selection period and then inventory burn-through; margin benefit is expected in Q4 or Q1 2027 depending on timing. Questions also focused on new products and cross-selling: management said PanTHERA remains on track for a Q4 launch, CryoCase has more than 3 dozen validations underway and could see customer announcements in the second half, and broader adoption is slowed by long validation cycles. On funding and market share, management said biotech funding mainly affects small early-stage customers and is not a major driver of BioLife’s revenue, while later-stage commercial programs and the move away from homebrew formulations should support share gains.
The core business is growing quickly, with 25% revenue growth and continued strength from BPM, which management says has dominant share and visibility from top customer forecasts. BioLife also has multiple embedded approved therapies, more than 250 commercially sponsored trials using its media, and a pipeline that could convert into future commercial revenue as programs advance. Management is optimistic that bag-yield issues are temporary, PanTHERA is nearing launch, and cross-selling could lift revenue per dose materially over time.
Gross margin is currently under pressure from bag mix and yield issues, and management said the recovery may not show through until Q4 or Q1 2027. New product and cross-selling opportunities are real but slow because large customers require lengthy validation and committee-driven decisions. The company also has a short-term debt maturity in June 2026 and cash declined quarter over quarter, partly due to working capital swings and tax-related payments.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.4%
- Shares Outstanding
- 48.86M
- Float Shares
- 42.68M
of shares held by institutions
221 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BLFS, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| T. Rowe Price Investment Management, Inc. | 6.75M | ▲ 244.79K |
| Blackrock, Inc. | 6.67M | ▲ 298.23K |
| Casdin Capital, LLC | 4.66M | ▼ 1.30M |
| Vanguard Group Inc | 3.09M | ▲ 119.87K |
| Vanguard Capital Management LLC | 2.00M | ▲ 31.38K |
| State Street Corp | 1.65M | ▼ 3.10K |
| First Trust Capital Management L.P. | 1.43M | ▲ 1.43M |
| Invesco Ltd. | 1.25M | ▼ 994.79K |
| Geode Capital Management, LLC | 1.14M | ▲ 49.35K |
| Magnetar Financial LLC | 1.09M | ▲ 1.09M |
| Fred Alger Management, LLC | 1.08M | ▼ 2.36K |
| Dimensional Fund Advisors LP | 1.04M | ▼ 4.83K |
Held by 85 ETFs
Biggest fund positions in BLFS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Wichterman Troy | other | 62,300 |
| Oct 6, 26 | Wichterman Troy | other | 76,204 |
| Oct 6, 26 | Wichterman Troy | other | 95,933 |
| Oct 6, 26 | Wichterman Troy | sell | 256,000 |
| Oct 6, 26 | GOSWAMI JOYDEEP | sell | 53,156 |
| Oct 6, 26 | Ellingson Rachel | sell | 57,995 |
| Oct 6, 26 | DuRoss Amy | sell | 26,857 |
| Oct 6, 26 | Coste Catherine | sell | 13,871 |
| Oct 6, 26 | DE GREEF RODERICK | other | 237,460 |
| Oct 6, 26 | DE GREEF RODERICK | other | 225,670 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BLFS coverage
Recent articles, reports, and earnings notes.
No research on BLFS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLFS report →BioLife Solutions Inc (BLFS) Shares Surge 3.5% -- What GF Score of 67 Tells Investors
gurufocus.com · Oct 23
BioLife Solutions Shareholders Approve Repligen Merger Agreement
marketbeat.com · Oct 5
BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Has Consensus Target Price of $31.38 According to Brokerages
defenseworld.net · Oct 5
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?
gurufocus.com · Sep 11
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?
prnewswire.com · Sep 11
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
businesswire.com · Sep 10
Bank of New York Mellon Corp Purchases New Shares in BioLife Solutions, Inc. $BLFS
defenseworld.net · Sep 5
Qiagen (NYSE:QGEN) & BioLife Solutions (NASDAQ:BLFS) Critical Contrast
defenseworld.net · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.